drugset / Trial / NCT02002611

Drug-drug Interaction Study(Lobeglitazone, Warfarin)

NCT02002611

Phase 1 Completed 24 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate a pharmacokinetic drug interaction between lobeglitazone and warfarin in healthy subjects.

Timeline

Start
2013-12
Primary completion
2014-02
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Lobeglitazone Small molecule 0.5 mg
Subject Warfarin Small molecule 25 mg